Amino acid conjugates of quetiapine, process for making and using the same

Patent metadata

Field	Value
Publication number	US-9597403-B2
Application number	US-201414216342-A
Country	US
Kind code	B2
Filing date	Mar 17, 2014
Priority date	Dec 31, 2009
Publication date	Mar 21, 2017
Grant date	Mar 21, 2017

Abstract

The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating amino acids to quetiapine. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology.

First claim

What is claimed is:

1. A composition for treating a psychiatric disorder in a subject comprising 2-(2-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethanol (quetiapine) conjugated to valine via an ester bond.

2. The composition of claim 1 , wherein the composition has a higher relative bioavailability than non-conjugated quetiapine when administered orally.

3. The composition of claim 1 , wherein the composition is formulated for oral or suppository administration.

4. The composition of claim 3 , wherein the composition formulated for oral administration is a tablet, capsule, caplet, pill, troche, lozenge, liquid solution, suspension, elixir or oral thin film.

5. The composition of claim 1 , wherein the conjugate is present in an amount of between about 1 mg and 2000 mg per unit dose.

6. The composition of claim 4 , wherein the conjugate is present in an amount of between about 150 and 800 mg per unit dose.

7. The composition of any one of claim 5 or 6 , wherein the presence of quetiapine is based on molar equivalent of unconjugated quetiapine.

8. The composition of claim 1 , further comprising one or more of: lithium, divalproex, antiadherents, binders, coatings, disintegrants, fillers, flavors and colors, glidants, lubricants, preservatives, sorbents and sweeteners.

9. The composition of claim 1 , wherein the composition comprises a salt of the conjugate.

10. The composition of claim 9 , wherein the salt is a hydrochloride salt, a hydrobromide salt, a hydroiodide salt, a sulfate, a phosphate, an organic acid salt, a nitrate, a benzoate or a mixture thereof.

11. The composition of claim 10 , wherein the organic acid salt is a mesylate salt, a besylate salt, a tosylate salt, an oxalate salt, a fumarate salt, a triflate salt, a citrate salt, a malate salt, or a tartarate salt.

12. A composition for treating schizophrenia in a subject-comprising a conjugate of quetiapine, an active metabolite of quetiapine or derivatives of quetiapine conjugated to valine wherein the conjugate is represented by any one of the following structures:

13. The composition of claim 12 , wherein the composition comprises a salt of the conjugate.

14. The composition of claim 13 , wherein the salt is a hydrochloride salt, a hydrobromide salt, a hydroiodide salt, a sulfate, a phosphate, an organic acid salt, a nitrate, a benzoate or a mixture thereof.

15. The composition of claim 14 , wherein the organic acid salt is a mesylate salt, a besylate salt, a tosylate salt, an oxalate salt, a fumarate salt, a triflate salt, a citrate salt, a malate salt, or a tartarate salt.

16. The composition of claim 1 , wherein the conjugate is a prodrug.

17. The composition of claim 16 , wherein the composition comprises a salt of the prodrug.

18. The composition of claim 1 , wherein the conjugate is a prodrug.

19. The composition of claim 18 , wherein the composition comprises a salt of the prodrug.

20. A method of treating schizophrenia comprising a step of administering to a subject a composition comprising a therapeutically effective amount of 2-(2-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethanol (quetiapine) conjugated to valine via an ester bond or a pharmaceutically acceptable salt thereof.

Assignees

• Kempharm Inc

Inventors

• Mickle Travis
• Guenther Sven
• Bera Sanjib

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61K31/553 Primary

  having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine · CPC title

• C07D267/18

  [b, e]-condensed · CPC title

• A61K31/554 Primary

  having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem · CPC title